Liver Angiosarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Angiosarcoma is a highly malignant neoplasm originating from the endothelial cells of blood or lymphatic vessels. It is characterized by the formation of abundant vascular channels due to the proliferation of spindle or pleomorphic cells that line or grow into the lumina of preexisting vascular spaces. In adults, primary hepatic angiosarcoma is the liver's most common primary malignant mesenchymal tumor. The etiology of the majority of these tumors remains unknown. However, several factors have been identified, including exposure to industrial materials, iatrogenic exposure to certain substances, and chronic ingestion of certain toxins. Hepatic angiosarcoma manifests as a hepatic bleeding mass and can sometimes present as a solid tumor. The tumor tends to metastasize to the lungs and hilar lymph nodes and spread to other organs such as the spleen and bones. Clinical tumour staging is based on the American Joint Committee on Cancer Staging System for soft tissue sarcoma, which considers factors such as tumor size, depth, and the presence of regional lymph nodes and distant metastases. Differential diagnosis of hepatic angiosarcoma includes inflammatory disorders of the liver, benign vascular diseases of the liver, and Kaposi sarcoma. The prognosis for patients with hepatic angiosarcoma is poor, with most patients dying within six months of diagnosis. Even with treatment, only a few patients survive beyond two years. Hepatic angiosarcoma is a rare tumor of the liver.
·
According to estimates, approximately 25 cases
of this tumor occur annually in the United States.
Thelansis’s “Liver Angiosarcoma Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2022 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Liver
Angiosarcoma treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Liver Angiosarcoma across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Liver Angiosarcoma Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment